The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDMX can interact with MDM2, leading to enhanced MDM2 stabilization and p53 degradation, but the full importance of the MDMX-MDM2 interaction is unclear (Marine et al., 2006; Wade et al., 2010).”
From p53 at a glance (2010) · cites this paper as Marine et al., 2006
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
Self-citationmdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
Self-citationThe MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Research works printed but not linked: 3
- Finch RA et al. (2002); 62: 3221–3225.
- Xiang S et al. (2006) Proc. Natl. Acad. Sci. USA. Feb 21 [Epub ahead of print].
- Francoz S et al. (2006) Proc. Natl. Acad. Sci. Feb 21 [Epub ahead of print].
Cited by
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
“A wealth of studies have delved into their interactions with p53 and have been well reviewed (Marine et al., 2006, 2007; Poyurovsky and Prives, 2006; Toledo and Wahl, 2006).”
BackgroundVousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Self-citationMutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
“Not surprisingly, both Mdm2 and MdmX are overexpressed in a variety of neoplasms (Marine et al. 2006).”
BackgroundStructural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693
p53 polymorphisms: cancer implications
Whibley, C., Pharoah, P. D. P., & Hollstein, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2584 · Cited by 665
Tumour suppression by p53: a role for the DNA damage response?
Meek, D. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2716 · Cited by 609
Targeting mutant p53 for cancer therapy: direct and indirect strategies
Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 483
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
p53 and E2f: partners in life and death
Polager, S., & Ginsberg, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2718 · Cited by 498
Matés, J. M., Segura, J. A., Alonso, F. J., & Márquez, J. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0304-z · Cited by 459
“The data support a model in which silencing of p53 in vivo, requires the synergistic action of both ubiquitin ligase oncogenic proteins (Marine et al. 2006).”
BackgroundThe p53 orchestra: Mdm2 and Mdmx set the tone
Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript Acknowledgments Research in the Wahl laboratory is funded in part by NIH grant CA061449 awarded to GMW. References 1.”
BackgroundInfluentialSelf-citationStructure–function–rescue: the diverse nature of common p53 cancer mutants
Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 434
“The transactivation domain interacts with a number of regulatory proteins, such as the negative regulator MDM2, which regulates cellular levels of p53 (Momand et al., 2000; Marine et al., 2006), components of the transcription initiation complex (Lu and Levine, 1995; Thut et al.”
BackgroundA complex barcode underlies the heterogeneous response of p53 to stress
Murray-Zmijewski, F., Slee, E. A., & Lu, X. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2451 · Cited by 420
Brady, C. A., & Attardi, L. D. (2010) · Journal of Cell Science · doi:10.1242/jcs.064501 · Cited by 403
“MDMX can interact with MDM2, leading to enhanced MDM2 stabilization and p53 degradation, but the full Journal of Cell Science 123 (15) Jo ur na l o f C el l S ci en ce 2530 importance of the MDMX-MDM2 interaction is unclear (Marine et al., 2006; Wade et al., 2010).”
BackgroundInfluentialThe Tumor Suppressor p53: From Structures to Drug Discovery
Joerger, A. C., & Fersht, A. R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000919 · Cited by 357
Transcription-independent p53 apoptosis: an alternative route to death
Speidel, D. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.10.002 · Cited by 356
Mdm2-mediated ubiquitylation: p53 and beyond
Marine, J.-C., & Lozano, G. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.68 · Cited by 354
Self-citationThe Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344
“The role of Mdm2 in regulating p53 by ubiquitination, as well as its interaction with MdmX, has been summarized recently in several excellent reviews (see Brooks and Gu 2006; Marine et al. 2006; Toledo and Wahl 2007; Kruse and Gu 2009; Marine and Lozano 2010; Wade et al. 2010).”
Backgroundp53-Mediated Hematopoietic Stem and Progenitor Cell Competition
Bondar, T., & Medzhitov, R. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.03.002 · Cited by 342
“The activity of p53 is highly sensitive to the level of Mdm2 (Marine et al., 2006).”
A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression
Okada, N., Lin, C.-P., Ribeiro, M. C., Biton, A., Lai, G., He, X., Bu, P., Vogel, H., Jablons, D. M., Keller, A. C., et al. (2014) · Genes & Development · doi:10.1101/gad.233585.113 · Cited by 297
“…as one major negative regulator of p53 (Marine et al. 2006; Markey and Berberich 2008; Mandke et al. 2012; Wade et al. 2013). mdm4/HDM4 and its closely related homolog, mdm2/HDM2, both encode RING domain proteins that promote oncogenesis by inhibiting p53 (Marine et al. 2006; Wade et al. 2013).”
BackgroundInfluentialThe Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 296
Cellular Stress Response Pathway System as a Sentinel Ensemble in Toxicological Screening
Simmons, S. O., Fan, C.-Y., & Ramabhadran, R. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp140 · Cited by 279
MDM2 and MDM4: p53 regulators as targets in anticancer therapy
Toledo, F., & Wahl, G. M. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.022 · Cited by 261
“The observation that MDM4-deficient embryos die around 10 dpc, apparently from p53-dependent cell proliferation arrest, showed that MDM4 is also an essential p53 regulator (Marine et al., 2006).”
BackgroundSelf-citationMdm2 Regulates p53 mRNA Translation through Inhibitory Interactions with Ribosomal Protein L26
Ofir-Rosenfeld, Y., Boggs, K., Michael, D., Kastan, M. B., & Oren, M. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.08.031 · Cited by 239
“…enhanced Mdm2 degradation, posttranslational modifications on p53 and Mdm2, altered binding to other proteins that modulate the p53-Mdm2 interaction and its consequences, and altered subcellular localization of p53 and Mdm2 (reviewed in Marine et al., 2006; Oren, 2003; Toledo and Wahl, 2006).”
BackgroundInfluentialSmalley, K. S. M., Contractor, R., Haass, N. K., Kulp, A. N., Atilla-Gokcumen, G. E., Williams, D. S., Bregman, H., Flaherty, K. T., Soengas, M. S., Meggers, E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1538 · Cited by 230
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization
Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203789109 · Cited by 230
“This is why they are frequently overproduced through gene amplification and/or overexpression in tumors that retain wildtype p53 (14).”
BackgroundMarine, J.-C. W., Dyer, M. A., & Jochemsen, A. G. (2007) · Journal of Cell Science · doi:10.1242/jcs.03362 · Cited by 228
“There is now clear genetic evidence indicating that Mdmx contributes to the regulation of p53 independently of Mdm2 and that both proteins act synergistically to keep p53 in check (Francoz et al., 2006; Marine et al., 2006).”
BackgroundSelf-citationp53-family proteins and their regulators: hubs and spokes in tumor suppression
Collavin, L., Lunardi, A., & Del Sal, G. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2010.35 · Cited by 220
Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy
Li, Q., & Lozano, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0053 · Cited by 190
Self-citationThe p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo
Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z.-G., Zuo, Y., Kawai, H., Shadfan, M., Ganapathy, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102309108 · Cited by 193
Outcomes of p53 activation - spoilt for choice
Vousden, K. H. (2006) · Journal of Cell Science · doi:10.1242/jcs.03293 · Cited by 189
“Clearly, activation of p53 in normal tissues following inducible loss of MDM2 can induce apoptosis in certain normal tissue types, which suggests that the tumour-to-normal-cell differential may not be as tight as one might have hoped (Marine et al., 2006).”
Backgroundp53 and NF‐κB: different strategies for responding to stress lead to a functional antagonism
Ak, P., & Levine, A. J. (2010) · The FASEB Journal · doi:10.1096/fj.10-160549 · Cited by 178
“MDM-2 functions in a heterodimeric complex with MDM-4, a related protein that can bind to p53 and MDM-4 and regulates MDM-2 activity (5).”
BackgroundBrooks, C. L., & Gu, W. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.05.022 · Cited by 186
“In one study, mutant knockout mice were generated that lacked p53 together with either mdm2 or mdmx [24–27].”
BackgroundRinaldo, C., Prodosmo, A., Mancini, F., Iacovelli, S., Sacchi, A., Moretti, F., & Soddu, S. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.008 · Cited by 174
“MDM2 is responsible for the maintenance of the basal, inactive state of p53 under normal conditions (Marine et al., 2006).”
BackgroundAn essential function of the extreme C-terminus of MDM2 can be provided by MDMX
Uldrijan, S., Pannekoek, W., & Vousden, K. H. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601469 · Cited by 170
“Studies in mice have indicated that an effect of MDMX on p53 stability, through the modulation of MDM2, can be seen in some but not all tissues (Marine et al, 2006).”
BackgroundInfluentialYadavilli, S., Mayo, L. D., Higgins, M., Laı́n, S., Hegde, V. K., & Deutsch, W. A. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.07.003 · Cited by 165
“Also, low levels of MDM2 induce monoubiquitination and nuclear export of p53, whereas high levels promote its polyubiquitination and nuclear degradation [3–6].”
p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome
Spike, B. T., & Wahl, G. M. (2011) · Genes & Cancer · doi:10.1177/1947601911410224 · Cited by 135
Self-citationRING Domain–Mediated Interaction Is a Requirement for MDM2's E3 Ligase Activity
Kawai, H., Lopez-Pajares, V., Kim, M. M., Wiederschain, D., & Yuan, Z.-M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1313 · Cited by 182
“These mouse genetic studies have further characterized the role of MDM2 and MDMX in controlling p53, concluding that the two proteins have distinct roles: MDM2 mediates the degradation of p53; MDMX inhibits p53 transcriptional activity (9).”
BackgroundInappropriate p53 activation during development induces features of CHARGE syndrome
Van Nostrand, J. L., Brady, C. A., Jung, H., Fuentes, D. R., Kozak, M. M., Johnson, T. M., Lin, C.-Y., Lin, C.-J., Swiderski, D. L., Vogel, H., et al. (2014) · Nature · doi:10.1038/nature13585 · Cited by 143
Chao, C. C. ‐. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.08.015 · Cited by 167
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wang, W., Albadari, N. G., Du, Y., Fowler, J. F., Sang, H. T., Xian, W., McKeon, F., Li, W., Zhou, J., & Zhang, R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001026 · Cited by 172
“Additionally, MDMX forms a heterodimer with MDM2, enhancing its stability and amplifying its ability to ubiquitinate p53 (Marine et al., 2006; Leslie et al., 2015).”
BackgroundThe p53–Mdm2–HAUSP complex is involved in p53 stabilization by HAUSP
Brooks, C. L., Li, M., Hu, M., Shi, Y., & Gu, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210531 · Cited by 147
“When p53 is not needed during times of cellular homeostasis, the protein is continuously ubiquitinated and degraded by Mdm2 (Marine et al., 2006).”
BackgroundAbbas, H. A., Macció, D. R., Coşkun, S., Jackson, J. G., Hazen, A. L., Sills, T., You, M. J., Hirschi, K. K., & Lozano, G. (2010) · Cell stem cell · doi:10.1016/j.stem.2010.09.013 · Cited by 155
“Additionally, conditional loss of both Mdm2 alleles in various adult tissues leads to cardiac, intestinal, and lymphoid defects resulting from constitutively active p53 (Marine et al., 2006).”
BackgroundSelf-citationGenetics and Epigenetics of Human Retinoblastoma
Benavente, C. A., & Dyer, M. A. (2015) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040259 · Cited by 147
Regulation of p53: a collaboration between Mdm2 and MdmX
Pei, D., Zhang, Y., & Zheng, J. (2012) · Oncotarget · doi:10.18632/oncotarget.443 · Cited by 140
“Mdm2 and MdmX proteins are found to exist in cells predominantly in the form of a heteroduplex [25], and structural studies have predicted that the formation of an Mdm2-MdmX heteroduplex is structurally favored over the formation of homoduplexes of either protein [28].”
BackgroundNew insights into p53 activation
Brooks, C. L., & Gu, W. (2010) · Cell Research · doi:10.1038/cr.2010.53 · Cited by 102
“Interestingly, the importance of MdmX for regulating p53 function was further strengthened from several in vivo mouse studies [69–71].”
BackgroundMolecular Basis for the Inhibition of p53 by Mdmx
Popowicz, G. M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L., & Holak, T. A. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4740 · Cited by 142
Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
AbuHammad, S., Cullinane, C. M., Martin, C., Bacolas, Z., Ward, T. A., Chen, H., Slater, A. A., Ardley, K., Kirby, L., Chan, K. T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901323116 · Cited by 136
“GSK3326595, on the other hand, induced p21and MDM2 gene expression in both parental and resistant cells (Fig.”
InfluentialCop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice
Migliorini, D., Bogaerts, S., Defever, D., Vyas, R., Denecker, G., Radaelli, E., Zwolińska, A., Depaepe, V., Hochepied, T., Skarnes, W. C., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45784 · Cited by 136
“Germline inactivation of Mdm2 and Mdmx , two key negative regulators of p53, indeed lead to embryonic lethality (26, 27).”
BackgroundResultSelf-citationMEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas
Balik, V., Srovnal, J., Sulla, I. J., Kalita, O., Foltánová, T., Vaverka, M., Hrabálek, L., & Hajdúch, M. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1038-6 · Cited by 133
Spotlight on the role of COP1 in tumorigenesis
Marine, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3271 · Cited by 126
Self-citationQuantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation
Wang, Y. V., Wade, M., Wong, E., Li, Y.-C., Rodewald, L. W., & Wahl, G. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701497104 · Cited by 116
Self-citationIto, M., Barys, L., O'Reilly, T., Young, S., Gorbatcheva, B., Monahan, J., Zumstein-Mecker, S., Choong, P. F., Dickinson, I., Crowe, P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2050 · Cited by 115
“Although embryonic lethality of either MDM2 or MDM4 nulls is rescued by deletion of Trp53 (mouse p53), a cooperative role for both encoded proteins in the inhibition of p53 with functional overlap has been proposed by several groups based on mouse genetic studies (6).”
BackgroundInfluentialZmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program
Bieging-Rolett, K. T., Kaiser, A. M., Morgens, D. W., Boutelle, A. M., Seoane, J. A., Nostrand, E. L. V., Zhu, C., Houlihan, S. L., Mello, S. S., Yee, B. A., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.022 · Cited by 117
“Interestingly, our data show that Zmat3 knockout cells are enriched for the full-length isoform of Mdm4 (Mdm4-FL), encoding the form that negatively regulates p53 by either directly blocking p53 transactivation or cooperating with the ubiquitin ligase MDM2 to promote p53 degradation (Marine et al., 2006; Toledo and Wa…”
BackgroundCK1α Plays a Central Role in Mediating MDM2 Control of p53 and E2F-1 Protein Stability
Huart, A.-S., MacLaine, N. J., Meek, D. W., & Hupp, T. R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.052647 · Cited by 110
Mdm2 Promotes Genetic Instability and Transformation Independent of p53
Bouska, A., Lushnikova, T., Plaza, S., & Eischen, C. M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01584-07 · Cited by 105
“ing of amino acids (aa) 1 to 228 (1-228) was generated by PCR and Mdm2”
BackgroundMethodMulay, S. R., Thomasová, D., Ryu, M., & Anders, H. (2012) · Kidney International · doi:10.1038/ki.2011.482 · Cited by 114
“, its E3 ligase activity that degrades p53 and its direct inhibitory effect on p53 activation.(40) Increased p53 activity mediates postWT Nutlin-3a Neutrophils (per h.”
BackgroundMSL2 Promotes Mdm2-independent Cytoplasmic Localization of p53
Kruse, J.-P., & Gu, W. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805658200 · Cited by 101
MdmX is a substrate for the deubiquitinating enzyme USP2a
Allende-Vega, N., Sparks, A., Lane, D. P., & Saville, M. K. (2010) · Oncogene · doi:10.1038/onc.2009.330 · Cited by 100
The Regulation of the p53-mediated Stress Response by MDM2 and MDM4
Perry, M. E. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000968 · Cited by 114
“Despite their many similarities, MDM2 and MDM4 differ functionally, as revealed by experiments with geneticallyengineered mice (reviewed by Marine et al. 2006).”
BackgroundA transcription co-factor integrates cell adhesion and motility with the p53 response
Coutts, A. S., Weston, L., & Thangue, N. B. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906785106 · Cited by 99
“The Mdm2 oncoprotein is a key regulator of the p53 response, a function it achieves by targeting p53 at multiple levels, including transcription, protein stability, and subcellular localization (6).”
BackgroundNew Insights in Thyroid Cancer and p53 Family Proteins
Manzella, L., Stella, S., Pennisi, M. S., Tirrò, E., Massimino, M., Romano, C., Puma, A., Tavarelli, M., & Vigneri, P. G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061325 · Cited by 99
“Both MDM2 and MDM4 negatively regulate p53 [44,45] (Figure 3C).”
Backgroundp53-Independent Effects of Mdm2
Bohlman, S., & Manfredi, J. J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_13 · Cited by 103
“Both phenotypes can be rescued by the loss of p53 [35, 48].”
BackgroundLozano, G. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001115 · Cited by 107
“Conditional alleles of Mdm2 and Mdm4 have been used to delete these genes in numerous cell types (Marine et al. 2006).”
BackgroundSelf-citationDifferential Roles of ATM- and Chk2-Mediated Phosphorylations of Hdmx in Response to DNA Damage
Pereg, Y., Lam, S., Teunisse, A., Biton, S., Meulmeester, E., Mittelman, L., Buscemi, G., Okamoto, K., Taya, Y., Shiloh, Y., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00562-06 · Cited by 93
“These reports proposed a model in which Mdm2 serves to mainly regulate p53 stability and Mdmx functions as a major inhibitor of p53 transcriptional activity (16, 29, 58, 64).”
BackgroundMdm2 and Mdm4 Loss Regulates Distinct p53 Activities
Barboza, J., Iwakuma, T., Terzian, T., El‐Naggar, A. K., & Lozano, G. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2079 · Cited by 106
“domain yielded lower p53 levels, albeit a more active p53 (20).”
BackgroundSelf-citationMendoza, M. J., Mandani, G., & Momand, J. A. (2013) · BioMolecular Concepts · doi:10.1515/bmc-2013-0027 · Cited by 96
“Careful mouse genetic studies indicate that MDM4 contributes more to inhibition of p53-mediated transcriptional transactivation while MDM2 contributes more to degradation of p53 (43).”
Pant, V., Xiong, S., Jackson, J. G., Post, S. M., Abbas, H. A., Quintás‐Cardama, A., Hamir, A. N., & Lozano, G. (2013) · Genes & Development · doi:10.1101/gad.227249.113 · Cited by 95
“A wealth of correlative evidence suggests that the p53– Mdm2 autoregulatory loop functions as the principal mode of p53 regulation under normal and DNA damage conditions (Haupt et al. 1997; Saucedo et al. 1998; Mendrysa and Perry 2000; Marine et al. 2006).”
BackgroundSelf-citationHuntington Disease as a Neurodevelopmental Disorder and Early Signs of the Disease in Stem Cells
Wiatr, K., Szlachcic, W. J., Trzeciak, M., Figlerowicz, M., & Figiel, M. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0477-7 · Cited by 102
“Embryonic lethality may be induced by disrupting p53 transactivation functions via the KO of the p53 regulators, the E3 ubiquitin-protein ligases: MDM2 or MDM4 [129], or the transcription activation domains, vital for interactions [130].”
BackgroundFenouille, N., Puissant, A., Tichet, M., Zimniak, G., Abbe, P., Mallavialle, A., Rocchi, S., Ortonne, J. ‐., Deckert, M., Ballotti, R., et al. (2011) · Oncogene · doi:10.1038/onc.2011.198 · Cited by 92
Reviving the guardian of the genome: Small molecule activators of p53
Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 86
“MDMX, also known asMDM4 (HDMX/HDM4 for its human analog), is structurally homologous to MDM2 and can both directly bind to and inhibit p53 as well as stabilize MDM2 to potentiate MDM2's ubiquitination capabilities (Gu et al., 2002; Marine et al., 2006; Shvarts et al., 1996).”
BackgroundGalluzzi, L., Morselli, E., Kepp, O., Vitale, I., Pinti, M., & Kroemer, G. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3504 · Cited by 87
“Negative regulation of p53 is crucial for organismal survival, as illustrated by the fact that mdm2 = mice die early during embryonic development as a direct consequence of the failure to restrain p53-mediated apoptosis (142).”
Bessler, M., Wilson, D. B., & Mason, P. J. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.05.019 · Cited by 84
“For example high levels of p53 expression in embryonic development causes cell death in neuronal cells and retina, moderate levels of p53 expression causes replicative senescence in hematopoietic progenitor cells, whereas low but chronic level of p53 expression causes senescence in pneumocytes and fibrosis in lung and…”
BackgroundSmall-Molecule Inhibitors of the p53-MDM2 Interaction
Vu, B. T., & Vassilev, L. T. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_110 · Cited by 87
Dysregulation of Glucose Metabolism by Oncogenes and Tumor Suppressors in Cancer Cells
Marbaniang, C., & Kma, L. (2018) · PubMed Central · doi:10.22034/apjcp.2018.19.9.2377 · Cited by 92
“In an unstressed cell, wild-type p53 is associated with an E3 ubiquitin ligase enzyme MDM2 that target p53 for degradation thus maintained the basal expression of p53 (Marine et al., 2006).”
BackgroundMancini, F., Conza, G. D., Pellegrino, M., Rinaldo, C., Prodosmo, A., Giglio, S., D’Agnano, I., Florenzano, F., Felicioni, L., Buttitta, F., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.154 · Cited by 97
Regulation of Metabolic Activity by p53
Flöter, J., Kaymak, I., & Schulze, A. (2017) · Metabolites · doi:10.3390/metabo7020021 · Cited by 81
“The low basal expression of p53 in unstressed cells is maintained by MDM2/HDM2 (mouse/human double minute 2 homolog) and MDM4 (also called MDMX) [10].”
BackgroundMcEvoy, J., Ulyanov, A., Brennan, R., Wu, G., Pounds, S., Zhang, J., & Dyer, M. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042739 · Cited by 80
Roles of HAUSP-mediated p53 regulation in central nervous system development
Kon, N., Zhong, J., Kobayashi, Y., Li, M., Szabolcs, M., Ludwig, T., Canoll, P. D., & Gu, W. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.12 · Cited by 79
“It has been well established that Mdm2 (murine double minute 2) is the major E3 ubiquitin ligase for p53.(9,13) Knockout of mdm2 in mice causes embryonic lethality due to p53 activation, whereas knockout of both mdm2 and p53 completely rescues the lethality.”
BackgroundWang, Y. V., Leblanc, M., Wade, M., Jochemsen, A. G., & Wahl, G. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.008 · Cited by 79
Self-citationMdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase
Okamoto, K., Taya, Y., & Nakagama, H. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.07.021 · Cited by 76
“Mdm2 and Mdmx function as two major players in the suppression of p53 activity [10].”
BackgroundEscape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14ARF-MDM2-p53 axis
Maerken, T. V., Vandesompele, J., Rihani, A., Paepe, A. D., & Speleman, F. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.138 · Cited by 82
Alstyne, M. V., Simon, C. M., Sardi, S. P., Shihabuddin, L. S., Mentis, G. Z., & Pellizzoni, L. (2018) · Genes & Development · doi:10.1101/gad.316059.118 · Cited by 83
“…we show that SMN deficiency disrupts the balance between inclusion and exclusion of key regulatory exons in Mdm2 and Mdm4 (two well-established effectors in the cellular control of p53) (Marine et al. 2006), leading to a switch in their biological activity from repression to activation of p53.”
BackgroundInfluentialIL-1 and EGF regulate expression of genes important in inflammation and cancer
Kasza, A. (2013) · Cytokine · doi:10.1016/j.cyto.2013.02.007 · Cited by 80
“DNA damage activates the kinases ATM and CHK-2, which phosphorylate MDM-2 leading to its inhibition and dissociation from MDM-4, respectively [123].”
BackgroundMdm2 affects genome stability independent of p53
Bouska, A., & Eischen, C. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3732 · Cited by 71
Steering the antitumor drug discovery campaign towards structurally diverse indolines
Thakur, A., Singh, A., Kaur, N., Ojha, R., & Nepali, K. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103436 · Cited by 72
p53 pathway is involved in cell competition during mouse embryogenesis
Zhang, G., Xie, Y., Zhou, Y., Xiang, C., Chen, L., Zhang, C., Hou, X., Chen, J., Zong, H., & Liu, G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617414114 · Cited by 69
“MDM2 functions as an E3 ubiquitin ligase responsible for the degradation of p53 (6), whereas MDM4, a homolog of MDM2, appears to inhibit p53 by masking its transcriptional activation domain (7).”
Backgroundc-Abl Phosphorylates Hdmx and Regulates Its Interaction with p53
Zuckerman, V., Lenos, K., Popowicz, G. M., Silberman, I., Grossman, T., Marine, J.-C., Holak, T. A., Jochemsen, A. G., & Haupt, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809211200 · Cited by 68
Self-citationSmall molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R. (2014) · Apoptosis · doi:10.1007/s10495-014-0990-3 · Cited by 59
“MDM2 amplifications) or loss of p19 [19, 20].”
Actual Proliferating Index and p53 protein expression as prognostic marker in odontogenic cysts
Gadbail, A. R., Chaudhary, M. S., Patil, S., & Gawande, M. N. (2009) · Oral Diseases · doi:10.1111/j.1601-0825.2009.01590.x · Cited by 67
Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene
Atwal, G. S., Kirchhoff, T., Bond, E. E., Montagna, M., Menin, C., Bertorelle, R., Scaini, M. C., Bartel, F., Böhnke, A., Pempe, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901298106 · Cited by 72
“In contrast, multiple studies have shown that the absence of the key negative regulators of p53, MDM2 and MDM4, in embryos results in early embryonic lethality, which is rescued by knocking out the p53 gene (8, 36).”
BackgroundChen, B., Longtine, M. S., Sadovsky, Y., & Nelson, D. M. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00154.2010 · Cited by 71
“MDMX, also called MDM4, is another negative regulator of p53 whose function does not overlap with MDM2 (27).”
BackgroundToledo, F., Lee, C. J., Krummel, K. A., Rodewald, L.-W., Liu, C.-W., & Wahl, G. M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00999-06 · Cited by 46
“Rather, consistent with other analyses, we postulate that the more critical regulatory targets in the p53 system are its negative regulators Mdm2 and Mdm4 (MdmX) and the various factors that control their abundance, stability, interactions with p53, and subcellular locations (13, 20, 28, 29).”
BackgroundSelf-citationThe Many Faces of MDM2 Binding Partners
Riley, M. F., & Lozano, G. (2012) · Genes & Cancer · doi:10.1177/1947601912455322 · Cited by 72
“2006).(1) The critical nature of the p53-Mdm2 relationship was first observed in animal models.”
BackgroundSelf-citationSystemic therapies for salivary gland adenoid cystic carcinoma.
Sahara, S., Herzog, A. E., & Nor, J. E. (2021) · PubMed · Cited by 73
Rong, J., Hu, R., Song, X., Ha, J., Lu, N., Qi, Q., Tao, L., You, Q., & Guo, Q. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.03.016 · Cited by 66
“Under normal condition, p53 is kept at low levels through ubiquitylation and proteasomal degradation, which is mediated mainly by negative regulator MDM2 and MDM4 [2,3].”
BackgroundDistinct roles of Mdm2 and Mdm4 in red cell production
Maetens, M., Doumont, G., Clercq, S. D., Francoz, S., Froment, P., Bellefroid, E., Klingmuller, U., Lozano, G., & Marine, J.-C. (2007) · Blood · doi:10.1182/blood-2006-03-013656 · Cited by 64
Self-citationHuang, Y.-N., Yang, L.-Y., Greig, N. H., Wang, Y.-C., Lai, C.-C., & Wang, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-19654-x · Cited by 68
Metadata
- Authors
- Marine, J.-C., Francoz, S., Maetens, M., Wahl, G., Toledo, F., & Lozano, G.
- Affiliations
- Vlaams Instituut voor Biotechnologie (BE)
- Salk Institute for Biological Studies (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Marine, J-C
- Venue
- Cell Death & Differentiation
- Published
- 2006-03-17
- Volume
- 13
- Issue
- 6
- Pages
- 927-934
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W2126832141
- Cited by
- 352
- References
- 27
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 12 · 2023: 12 · 2022: 8 · 2021: 9 · 2020: 16 · 2019: 12 · 2018: 16 · 2017: 16 · 2016: 14 · 2015: 14 · 2014: 26 · 2013: 17 · 2012: 27
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Death and Differentiation (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, MDM2, MDM4, p53 regulation, tumor suppressor, DNA damage response, oxidative stress, oncogene activation, mitotic stress, cell cycle arrest, apoptosis, p21, pro-apoptotic genes, p53 target genes
- MeSH terms
- Animals, Antineoplastic Agents, Cell Differentiation, Humans, Neurons, Phenotype, Promoter Regions, Genetic, Protein Processing, Post-Translational, Proto-Oncogene Proteins, Stem Cells, Transcriptional Activation, Tumor Suppressor Protein p53, Apoptosis, Mice, Knockout, Gene Expression Regulation, Developmental, Ubiquitin, Ubiquitin-Protein Ligases, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.